UNLABELLED: Chemokines, chemotactic cytokines, may promote hepatic inflammation in chronic hepatitis C virus (HCV) infection through the recruitment of lymphocytes to the liver parenchyma. We evaluated the association between inflammation and fibrosis and CXCR3-associated chemokines, interferon-gamma (IFN-gamma)-inducible protein 10 (IP-10/CXCL10), monokine induced by IFN-gamma (Mig/CXCL9), and interferon-inducible T cell alpha chemoattractant (I-TAC/CXCL11), in HCV infection. Intrahepatic mRNA expression of these chemokines was analyzed in 106 chronic HCV-infected patients by real-time PCR. The intrahepatic localization of chemokine producer cells and CXCR3(+) lymphocytes was determined in selected patients by immunohistochemistry. We found elevated intrahepatic mRNA expression of all three chemokines, most markedly CXCL10, in chronic HCV-infected patients with higher necroinflammation and fibrosis. By multivariable multivariate analysis, intrahepatic CXCL10 mRNA expression levels were significantly associated with lobular necroinflammatory grade and HCV genotype 1. In the lobular region, CXCL10-expressing and CXCL9-expressing hepatocytes predominated in areas with necroinflammation. Strong CXCL11 expression was observed in almost all portal tracts, whereas CXCL9 expression varied considerably among portal tracts in the same individual. Most intrahepatic lymphocytes express the CXCR3 receptor, and the number of CXCR3(+) lymphocytes was increased in patients with advanced necroinflammation. CONCLUSION: These findings suggest that the CXCR3-associated chemokines, particularly CXCL10, may play an important role in the development of necroinflammation and fibrosis in the liver parenchyma in chronic HCV infection.
UNLABELLED: Chemokines, chemotactic cytokines, may promote hepatic inflammation in chronic hepatitis C virus (HCV) infection through the recruitment of lymphocytes to the liver parenchyma. We evaluated the association between inflammation and fibrosis and CXCR3-associated chemokines, interferon-gamma (IFN-gamma)-inducible protein 10 (IP-10/CXCL10), monokine induced by IFN-gamma (Mig/CXCL9), and interferon-inducible T cell alpha chemoattractant (I-TAC/CXCL11), in HCV infection. Intrahepatic mRNA expression of these chemokines was analyzed in 106 chronic HCV-infectedpatients by real-time PCR. The intrahepatic localization of chemokine producer cells and CXCR3(+) lymphocytes was determined in selected patients by immunohistochemistry. We found elevated intrahepatic mRNA expression of all three chemokines, most markedly CXCL10, in chronic HCV-infectedpatients with higher necroinflammation and fibrosis. By multivariable multivariate analysis, intrahepatic CXCL10 mRNA expression levels were significantly associated with lobular necroinflammatory grade and HCV genotype 1. In the lobular region, CXCL10-expressing and CXCL9-expressing hepatocytes predominated in areas with necroinflammation. Strong CXCL11 expression was observed in almost all portal tracts, whereas CXCL9 expression varied considerably among portal tracts in the same individual. Most intrahepatic lymphocytes express the CXCR3 receptor, and the number of CXCR3(+) lymphocytes was increased in patients with advanced necroinflammation. CONCLUSION: These findings suggest that the CXCR3-associated chemokines, particularly CXCL10, may play an important role in the development of necroinflammation and fibrosis in the liver parenchyma in chronic HCV infection.
Authors: P M Murphy; M Baggiolini; I F Charo; C A Hébert; R Horuk; K Matsushima; L H Miller; J J Oppenheim; C A Power Journal: Pharmacol Rev Date: 2000-03 Impact factor: 25.468
Authors: M Diago; G Castellano; J García-Samaniego; C Pérez; I Fernández; M Romero; O L Iacono; C García-Monzón Journal: Gut Date: 2005-09-08 Impact factor: 23.059
Authors: Ana I Romero; Martin Lagging; Johan Westin; Amar P Dhillon; Lynn B Dustin; Jean-Michel Pawlotsky; Avidan U Neumann; Carlo Ferrari; Gabriele Missale; Bart L Haagmans; Solko W Schalm; Stefan Zeuzem; Francesco Negro; Elke Verheij-Hart; Kristoffer Hellstrand Journal: J Infect Dis Date: 2006-08-29 Impact factor: 5.226
Authors: L Martin Lagging; Johan Westin; Elisabeth Svensson; Nibia Aires; Amar P Dhillon; Magnus Lindh; Rune Wejstål; Gunnar Norkrans Journal: Liver Date: 2002-04
Authors: S Johansson; W Talloen; M Tuefferd; J M Darling; A Scholliers; G Fanning; M W Fried; J Aerssens Journal: Aliment Pharmacol Ther Date: 2015-08-28 Impact factor: 8.171
Authors: Armanda Casrouge; Jérémie Decalf; Mina Ahloulay; Cyril Lababidi; Hala Mansour; Anaïs Vallet-Pichard; Vincent Mallet; Estelle Mottez; James Mapes; Arnaud Fontanet; Stanislas Pol; Matthew L Albert Journal: J Clin Invest Date: 2010-12-22 Impact factor: 14.808
Authors: Jason Grebely; Jordan J Feld; Tanya Applegate; Gail V Matthews; Margaret Hellard; Alana Sherker; Kathy Petoumenos; Geng Zang; Ineke Shaw; Barbara Yeung; Jacob George; Suzy Teutsch; John M Kaldor; Vera Cherepanov; Julie Bruneau; Naglaa H Shoukry; Andrew R Lloyd; Gregory J Dore Journal: Hepatology Date: 2013-05-08 Impact factor: 17.425
Authors: Andrew H Talal; Rositsa B Dimova; Eileen Z Zhang; Min Jiang; Marina S Penney; James C Sullivan; Martyn C Botfield; Ananthsrinivas Chakilam; Rishikesh Sawant; Christine M Cervini; Marija Zeremski; Ira M Jacobson; Ann D Kwong Journal: Hepatology Date: 2014-07-31 Impact factor: 17.425